Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Safusidenib (AB-218, DS-1001)

SIGMA

Nuvation Bio · Phase 3 · Recruiting · Enrollment 365

NCT05303519

Catalyst Primary completion. 12.01.2028. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmReported safety

A count stays a count. This page does not turn a count into a percent.